Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Medicines Co. Enters PCSK9 Race With Alnylam Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

The Medicines Company and RNAi therapeutics company Alnylam have teamed up to develop a new drug targeting PCSK9 for the treatment of high cholesterol, but they are far behind the leaders in the pack and will have to differentiate their product from the others in the race.


Related Content

Alnylam Advancing From Platform Buzz To Late-Stage Clinical Work
Can MDCO Make Alnylam’s PCSK9 Candidate Work In The Hospital?
Sanofi/Regeneron’s PSCK9 Inhibitor Alirocumab Passes First Phase III Test
TMC Likes Its Options: Hospital Marketer Gains Rights To ProFibrix
Biopharma Dealmaking Quarterly Statistics, Q1 2013
The Medicines Co. Plans Mid-2013 Regulatory Submissions For Two Key R&D Assets
Deals Of The Week: Alnylam/The Medicines Co., Inspiration/Cangene, Pfizer/OxOnc
The Alnylam Turnaround: What Changed Investors’ Minds?
Branded Life After Lipitor: Pharma Targets Unmet Needs In Dyslipidemia


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts